NYSE$PLX
Protalix Biotherapeutics Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2020, and provided a business update on recent corporate and clinical developments.
Protalix reports a transformational first quarter in 2020, closing a $43.7 million private placement and submitting a BLA for PRX-102 after completing the Phase III BRIDGE study.
- Closed a $43.7 million private placement.
- Completed Phase III BRIDGE study.
- Submitted BLA for PRX-102.
- Adapted quickly to the changing environment despite the COVID-19 pandemic.
Headline financials
Revenue & EPS history
Protalix · Revenue · Quarterly
$21.6M
Revenue by segment
Protalix · $3.18M total across 1 segment · Q2 2021
- License & R&D$3.18M—100.0%
Forward guidance
Protalix is positioned for long-term success and looks forward to continuing momentum through the rest of this year and into 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2020
-1.3%
Avg return
Earnings day
-1.7%
Avg return
5 days after
-5.6%
Avg return
30 days after
44%
28 / 64 earnings
Positive
+15.7%
Q2 2023
Best reaction
-36.4%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.1% | +0.0% | +9.5% | |
| Q4 2025 | +1.8% | -23.7% | -16.8% | |
| Q3 2025 | -10.9% | -12.1% | -16.4% | |
| Q1 2025 | +0.0% | +2.4% | -10.8% | |
| Q4 2024 | +9.4% | +11.2% | +16.1% | |
| Q3 2024 | +12.9% | +31.5% | +45.2% | |
| Q2 2024 | -8.7% | -7.7% | +1.0% | |
| Q1 2024 | -8.8% | -9.6% | -10.4% | |
| Q4 2023 | -12.5% | -14.5% | -22.4% | |
| Q3 2023 | -18.9% | -27.6% | -14.1% | |
| Q2 2023 | +15.7% | +15.7% | +13.9% | |
| Q1 2023 | +3.8% | -7.3% | -29.8% | |
| Q4 2022 | +6.6% | +12.6% | +11.0% | |
| Q3 2022 | +0.9% | +1.9% | +10.5% | |
| Q2 2022 | -0.4% | -2.4% | -11.4% | |
| Q1 2022 | +0.9% | +7.5% | +1.9% | |
| Q4 2021 | +0.0% | +40.0% | +10.5% | |
| Q3 2021 | -3.5% | -14.0% | -21.9% | |
| Q2 2021 | +2.2% | +0.0% | -0.7% | |
| Q1 2021 | +0.7% | -1.0% | -24.4% | |
| Q4 2020 | -5.1% | -4.5% | -24.7% | |
| Q3 2020 | -7.9% | -9.3% | +2.0% | |
| Q2 2020 | +2.2% | +3.3% | -6.1% | |
| Q1 2020 | +2.7% | +7.5% | +12.3% | |
| Q4 2019 | -3.0% | -5.1% | +3.8% | |
| Q3 2019 | -5.2% | -8.7% | +34.8% | |
| Q2 2019 | -36.4% | -29.7% | -40.5% | |
| Q1 2019 | -2.7% | -6.8% | -15.9% | |
| Q4 2018 | +1.8% | -6.1% | -12.2% | |
| Q3 2018 | -5.2% | -14.3% | -12.2% | |
| Q2 2018 | -2.0% | +0.0% | -6.0% | |
| Q1 2018 | +2.2% | +12.5% | +15.0% | |
| Q4 2017 | -1.4% | +1.5% | -33.8% | |
| Q3 2017 | -6.6% | -1.4% | -15.1% | |
| Q2 2017 | -4.6% | -12.3% | -4.6% | |
| Q1 2017 | -6.0% | -13.0% | -5.4% | |
| Q4 2016 | -4.7% | -14.1% | -18.0% | |
| Q3 2016 | +12.1% | +34.1% | -26.8% | |
| Q2 2016 | -1.5% | -1.6% | -4.7% | |
| Q1 2016 | -0.6% | — | — | |
| Q4 2015 | +4.7% | — | — | |
| Q3 2015 | -3.8% | — | — | |
| Q2 2015 | +3.8% | — | — | |
| Q1 2015 | +1.4% | — | — | |
| Q4 2014 | -5.4% | — | — | |
| Q3 2014 | -1.5% | — | — | |
| Q2 2014 | -1.3% | — | — | |
| Q1 2014 | -0.5% | — | — | |
| Q4 2013 | -2.5% | — | — | |
| Q3 2013 | +0.2% | — | — | |
| Q2 2013 | +4.3% | — | — | |
| Q1 2013 | -1.1% | — | — | |
| Q4 2012 | +4.0% | — | — | |
| Q3 2012 | +1.3% | — | — | |
| Q2 2012 | +1.4% | — | — | |
| Q1 2012 | +2.8% | — | — | |
| Q4 2011 | -1.5% | — | — | |
| Q3 2011 | +1.3% | — | — | |
| Q2 2011 | -9.7% | — | — | |
| Q1 2011 | -0.8% | — | — | |
| Q4 2010 | -1.3% | — | — | |
| Q3 2010 | -4.4% | — | — | |
| Q2 2010 | +0.1% | — | — | |
| Q1 2010 | +6.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro